Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M90,167Revenue (TTM) $M30,390Net Margin (%)44.4Altman Z-Score3.6
Enterprise Value $M57,787EPS (TTM) $9.9Operating Margin %58.0Piotroski F-Score5
P/E(ttm)7.1Beneish M-Score-2.6Pre-tax Margin (%)56.2Higher ROA y-yN
Price/Book4.610-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsN
Price/Sales3.25-y EBITDA Growth Rate %55.0Current Ratio4.2Lower Leverage y-yY
Price/Free Cash Flow7.7y-y EBITDA Growth Rate %-11.6ROA % (ttm)25.6Higher Current Ratio y-yY
Dividend Yield %2.7PEG0.1ROE % (ttm)80.3Less Shares Outstanding y-yY
Payout Ratio %17.0Shares Outstanding M1,310ROIC % (ttm)67.7Gross Margin Increase y-yN

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

GILD is held by these investors:

GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARTIN JOHN CExecutive Chairman 2017-02-01Sell73,333$72.57-5.25view
MARTIN JOHN CExecutive Chairman 2017-01-03Sell73,337$73.59-6.56view
MARTIN JOHN CExecutive Chairman 2016-12-01Sell100,000$73.33-6.23view
MADIGAN JOHN WDirector 2016-11-18Sell105,000$74.86-8.15view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-11-09Sell10,000$79-12.96view
MARTIN JOHN CExecutive Chairman 2016-11-01Sell100,000$73.76-6.78view
MARTIN JOHN CExecutive Chairman 2016-10-03Sell100,000$77.63-11.43view
Alton Gregg HEVP Comm&Acs ALA, Corp&Med Aff 2016-09-22Sell5,000$81.84-15.98view
MILLIGAN JOHN FPresident and CEO 2016-09-06Sell70,000$77.74-11.55view
MARTIN JOHN CExecutive Chairman 2016-09-01Sell100,000$77.48-11.25view

Quarterly/Annual Reports about GILD:

News about GILD:

Articles On GuruFocus.com
10 Undervalued Stocks for the Enterprising Investor Feb 16 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
Consider Gilead Sciences Feb 14 2017 
Gilead Sciences, Fossil Reach 3-Year Low Prices Feb 12 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
10 Low PE Stock Picks for the Enterprising Investor Feb 04 2017 
5 Companies Near 52-Week Lows Feb 03 2017 
John Paulson's Bargain Stock Jan 30 2017 
10 Undervalued Stocks for the Enterprising Investor Jan 26 2017 
6 Stocks Trading Below Peter Lynch Value Jan 26 2017 

More From Other Websites
Gilead Sciences Expects to Witness an Earnings Fall in 2017 Feb 22 2017
Gilead Sciences Expects to See a Revenue Fall in 2017 Feb 22 2017
Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs Feb 22 2017
Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments Feb 22 2017
What Are Analysts’ Recommendations for Gilead Sciences in 2017? Feb 22 2017
Ontario Becomes First Province To List EPCLUSA™ On Public Drug Plan To Treat All Six Genotypes Of... Feb 22 2017
[$$] Gilead Goes to the Head of the Line Feb 22 2017
Did Gilead's new tool for speeding drug approval come at bargain-basement price? Feb 21 2017
[$$] Gilead Goes to the Head of the Line Feb 21 2017
Sarepta Sells Priority Review Voucher for $125M Feb 21 2017
Sarepta sells FDA review voucher for $125M, but analyst questions price Feb 21 2017
Gilead Sells Anti-Addiction Drug to Amygdala Feb 20 2017
Your Burning Biotech Questions Answered Feb 20 2017
Gilead Receives Approval in Canada for ODEFSEY™ for the Treatment of HIV-1 Infection Feb 16 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)